Key result
Ergot derivative dopamine agonists were associated with a higher frequency of >grade 3 valvular regurgitation compared to non-ergot users and controls (24% vs 0% vs 3%, p=0.001).
Why the study?
Does plasma BNP correlate with the severity of cardiovalvulopathy in Parkinson disease patients treated with ergot derivative dopamine agonists?
Observational (n=80)
Does plasma BNP correlate with the severity of cardiovalvulopathy in Parkinson disease patients treated with ergot derivative dopamine agonists?
Absolute Event Rate: 24% vs 0%
p-value: p=0.001
Plasma BNP levels combined with comprehensive echocardiography are useful for detecting and evaluating cardiovalvulopathy in Parkinson disease patients treated with ergot derivative dopamine agonists.
Ergot agonists may raise severe regurgitation risk in Parkinson disease; leaves open BNP's incremental value for screening.
OBJECTIVE: To elucidate the usefulness of plasma B-type natriuretic peptide (BNP) values for evaluating adverse effects of pergolide or cabergoline on cardiovalvulopathy in patients with Parkinson disease. METHODS: Twenty-five patients treated with pergolide or cabergoline (ergot group) and 25 patients never treated with ergot derivatives (non-ergot group) were enrolled. Plasma BNP values and detailed echocardiography were evaluated. Thirty age- and gender-matched controls were similarly evaluated. RESULTS: Patients with regurgitation more than grade 3 were more frequent in the ergot group than in the non-ergot group as well as control groups (24%, 0%, 3%, p = 0.001). Both composite regurgitation scores and plasma BNP values were significantly higher in the ergot group than in controls. In the ergot group, the cumulative dose correlated to both tenting area (r = 0.57, p = 0.004) and tenting distance (r = 0.62, p = 0.001). Furthermore, plasma BNP values were higher in patients with severe or multiple regurgitation groups (p < 0.001), and were correlated with composite regurgitation score (r = 0.70, p < 0.001). Multiple regression analyses revealed that BNP values were independently correlated with both composite regurgitation and left ventricular ejection fraction. CONCLUSION: The combination of comprehensive echocardiography and plasma B-type natriuretic peptide levels elucidates the presence of cardiac damage in patients with Parkinson disease using ergot derivative dopamine agonists.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2009) conducted an observational in Parkinson disease (n=80). Ergot derivative dopamine agonists (pergolide or cabergoline) vs. Non-ergot treated Parkinson disease patients and healthy controls was evaluated on Regurgitation more than grade 3 (p=0.001). Ergot derivative dopamine agonists were associated with a higher frequency of >grade 3 valvular regurgitation compared to non-ergot users and controls (24% vs 0% vs 3%, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: